TY - JOUR
T1 - MEF2C Hypofunction in Neuronal and Neuroimmune Populations Produces MEF2C Haploinsufficiency Syndrome–like Behaviors in Mice
AU - Harrington, Adam J.
AU - Bridges, Catherine M.
AU - Berto, Stefano
AU - Blankenship, Kayla
AU - Cho, Jennifer Y.
AU - Assali, Ahlem
AU - Siemsen, Benjamin M.
AU - Moore, Hannah W.
AU - Tsvetkov, Evgeny
AU - Thielking, Acadia
AU - Konopka, Genevieve
AU - Everman, David B.
AU - Scofield, Michael D.
AU - Skinner, Steven A.
AU - Cowan, Christopher W.
N1 - Funding Information:
This work was supported in part by the National Institutes of Health (Grant No. R01 MH111464 [to CWC] and Grant Nos. TL1 TR001451 , UL1 TR001450 , and F30 HD098893 [to CMB]), Brain and Behavior Research Foundation (National Alliance for Research on Schizophrenia and Depression Young Investigator Award [to AJH]), and Simons Foundation (Simons Foundation Autism Research Initiative Pilot Grant No. 649452 [to CWC]). This work was conducted in a facility constructed with support from National Institutes of Health Grant No. C06 RR015455.
Funding Information:
We thank Dr. Patrick J. Mulholland and the Shared Confocal Core Facility (supported by National Institutes of Health Grant No. S10 OD021532), Dr. Jeremy L. Barth and the Medical University of South Carolina Proteogenomics Facility for the quantitative polymerase chain reaction instrument (supported by National Institute of General Medical Sciences Grant No. GM103499 and Medical University of South Carolina Office of the Vice President for Research), and Duncan Nowling for technical assistance.
Funding Information:
This work was supported in part by the National Institutes of Health (Grant No. R01 MH111464 [to CWC] and Grant Nos. TL1 TR001451, UL1 TR001450, and F30 HD098893 [to CMB]), Brain and Behavior Research Foundation (National Alliance for Research on Schizophrenia and Depression Young Investigator Award [to AJH]), and Simons Foundation (Simons Foundation Autism Research Initiative Pilot Grant No. 649452 [to CWC]). This work was conducted in a facility constructed with support from National Institutes of Health Grant No. C06 RR015455. AJH, CMB, AA, and CWC designed experiments, performed data analysis, and wrote the manuscript. HWM, DBE, and SAS collected MCHS patient data. AJH, CMB, KB, JYC, and AA performed behavior tests and analyzed data. SB and GK analyzed RNA-seq data. ET performed electrophysiology and data analysis. BMS and MDS performed dendritic spine morphology experiments. AJH, CMB, KB, JYC, and AT performed molecular/biochemical experiments and data analysis. AJH and CMB performed statistical analyses. We thank Dr. Patrick J. Mulholland and the Shared Confocal Core Facility (supported by National Institutes of Health Grant No. S10 OD021532), Dr. Jeremy L. Barth and the Medical University of South Carolina Proteogenomics Facility for the quantitative polymerase chain reaction instrument (supported by National Institute of General Medical Sciences Grant No. GM103499 and Medical University of South Carolina Office of the Vice President for Research), and Duncan Nowling for technical assistance. The authors report no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2020 Society of Biological Psychiatry
PY - 2020/9/15
Y1 - 2020/9/15
N2 - Background: Microdeletions of the MEF2C gene are linked to a syndromic form of autism termed MEF2C haploinsufficiency syndrome (MCHS). MEF2C hypofunction in neurons is presumed to underlie most of the symptoms of MCHS. However, it is unclear in which cell populations MEF2C functions to regulate neurotypical development. Methods: Multiple biochemical, molecular, electrophysiological, behavioral, and transgenic mouse approaches were used to characterize MCHS-relevant synaptic, behavioral, and gene expression changes in mouse models of MCHS. Results: We showed that MCHS-associated missense mutations cluster in the conserved DNA binding domain and disrupt MEF2C DNA binding. DNA binding–deficient global Mef2c heterozygous mice (Mef2c-Het) displayed numerous MCHS-related behaviors, including autism-related behaviors, changes in cortical gene expression, and deficits in cortical excitatory synaptic transmission. We detected hundreds of dysregulated genes in Mef2c-Het cortex, including significant enrichments of autism risk and excitatory neuron genes. In addition, we observed an enrichment of upregulated microglial genes, but this was not due to neuroinflammation in the Mef2c-Het cortex. Importantly, conditional Mef2c heterozygosity in forebrain excitatory neurons reproduced a subset of the Mef2c-Het phenotypes, while conditional Mef2c heterozygosity in microglia reproduced social deficits and repetitive behavior. Conclusions: Taken together, our findings show that mutations found in individuals with MCHS disrupt the DNA-binding function of MEF2C, and DNA binding–deficient Mef2c global heterozygous mice display numerous MCHS-related phenotypes, including excitatory neuron and microglia gene expression changes. Our findings suggest that MEF2C regulates typical brain development and function through multiple cell types, including excitatory neuronal and neuroimmune populations.
AB - Background: Microdeletions of the MEF2C gene are linked to a syndromic form of autism termed MEF2C haploinsufficiency syndrome (MCHS). MEF2C hypofunction in neurons is presumed to underlie most of the symptoms of MCHS. However, it is unclear in which cell populations MEF2C functions to regulate neurotypical development. Methods: Multiple biochemical, molecular, electrophysiological, behavioral, and transgenic mouse approaches were used to characterize MCHS-relevant synaptic, behavioral, and gene expression changes in mouse models of MCHS. Results: We showed that MCHS-associated missense mutations cluster in the conserved DNA binding domain and disrupt MEF2C DNA binding. DNA binding–deficient global Mef2c heterozygous mice (Mef2c-Het) displayed numerous MCHS-related behaviors, including autism-related behaviors, changes in cortical gene expression, and deficits in cortical excitatory synaptic transmission. We detected hundreds of dysregulated genes in Mef2c-Het cortex, including significant enrichments of autism risk and excitatory neuron genes. In addition, we observed an enrichment of upregulated microglial genes, but this was not due to neuroinflammation in the Mef2c-Het cortex. Importantly, conditional Mef2c heterozygosity in forebrain excitatory neurons reproduced a subset of the Mef2c-Het phenotypes, while conditional Mef2c heterozygosity in microglia reproduced social deficits and repetitive behavior. Conclusions: Taken together, our findings show that mutations found in individuals with MCHS disrupt the DNA-binding function of MEF2C, and DNA binding–deficient Mef2c global heterozygous mice display numerous MCHS-related phenotypes, including excitatory neuron and microglia gene expression changes. Our findings suggest that MEF2C regulates typical brain development and function through multiple cell types, including excitatory neuronal and neuroimmune populations.
KW - Autism
KW - Mef2c
KW - Microglia
KW - Mouse
KW - Neurodevelopmental disorder
KW - Neuron
UR - http://www.scopus.com/inward/record.url?scp=85084565209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084565209&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2020.03.011
DO - 10.1016/j.biopsych.2020.03.011
M3 - Article
C2 - 32418612
AN - SCOPUS:85084565209
SN - 0006-3223
VL - 88
SP - 488
EP - 499
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 6
ER -